Mechanism of action
Dicyclomine is a tertiary amine antimuscarinic agent that competitively blocks muscarinic acetylcholine receptors (M1, M2, and M3 subtypes) in the gastrointestinal tract and other tissues. By antagonizing muscarinic receptors on smooth muscle cells in the gut wall, it reduces parasympathetic tone and decreases smooth muscle contractility, thereby relieving intestinal spasm and cramping.
The drug also exhibits some direct relaxant effect on smooth muscle independent of its antimuscarinic action, though this is a minor component of its therapeutic effect. Blockade of M3 receptors on gastrointestinal smooth muscle is primarily responsible for the antispasmodic effect. As a nonselective antimuscarinic, dicyclomine also affects muscarinic receptors in salivary glands, eyes, bladder, and other tissues, producing typical anticholinergic side effects.
Unlike some antispasmodics, dicyclomine crosses the blood-brain barrier to a limited extent due to its tertiary amine structure, which can contribute to central anticholinergic effects such as dizziness and confusion, particularly in elderly patients or at higher doses.
- Dicyclomine is absolutely contraindicated in infants <6 months due to risk of respiratory arrest and death.
- Antimuscarinic mechanism: blocks M3 receptors on GI smooth muscle to reduce spasm and cramping.
- Classic anticholinergic side effects: dry mouth, blurred vision, urinary retention, constipation, tachycardia.
- Contraindicated in narrow-angle glaucoma, myasthenia gravis, paralytic ileus, and obstructive uropathy.
- Appears on Beers Criteria as potentially inappropriate in elderly due to high anticholinergic burden.
- Anticholinergic toxidrome mnemonic: hot, blind, dry, red, mad; treat severe cases with physostigmine.
- May precipitate acute angle-closure glaucoma in susceptible individuals due to mydriasis.
- Additive anticholinergic effects with TCAs, antihistamines, antipsychotics, and other antimuscarinics increase toxicity risk.
Indications
Dicyclomine is indicated for the treatment of functional bowel disorders and irritable bowel syndrome (IBS), particularly when abdominal cramping and spasm are prominent symptoms. It provides symptomatic relief of smooth muscle spasm in the gastrointestinal tract.
Primary indication:
- Irritable bowel syndrome (symptomatic relief of abdominal pain and cramping)
Other uses:
- Functional gastrointestinal disorders with smooth muscle spasm
- Adjunctive therapy in peptic ulcer disease (historical use, now uncommon)
- Infantile colic (no longer recommended due to serious safety concerns)
Dicyclomine does not treat the underlying cause of IBS or functional GI disorders but provides symptomatic relief during acute episodes. It is typically used intermittently rather than as continuous long-term therapy. The drug is not effective for constipation-predominant IBS and may worsen constipation due to its anticholinergic effects on gut motility.
Pharmacokinetics
Dicyclomine is administered orally and exhibits the following pharmacokinetic profile:
Absorption: Readily absorbed from the gastrointestinal tract after oral administration. Peak plasma concentrations occur approximately 1 to 1.5 hours after dosing. Food does not significantly affect absorption.
Distribution: Widely distributed throughout the body. As a tertiary amine, it has some ability to cross the blood-brain barrier, though penetration is limited. The volume of distribution is substantial, reflecting tissue uptake.
Metabolism: Extensively metabolized in the liver, primarily through enzymatic pathways. The drug undergoes both hepatic and probably intestinal metabolism. Specific cytochrome P450 isoenzymes involved have not been fully characterized.
Elimination: Excreted in urine and feces. Approximately 80% is excreted in urine as metabolites and unchanged drug, with about 10% appearing in feces. The elimination half-life is approximately 9 to 10 hours in adults, allowing for dosing every 6 to 8 hours.
Special populations: Elderly patients may experience prolonged effects due to reduced renal and hepatic clearance. Dosage adjustment may be necessary in hepatic or renal impairment, though specific guidelines are not well established.
Adverse effects
Dicyclomine produces adverse effects typical of antimuscarinic agents, with severity generally related to dose.
Common anticholinergic effects:
- Dry mouth (xerostomia) — most frequent complaint
- Blurred vision and mydriasis (pupil dilation)
- Constipation
- Urinary hesitancy or retention
- Dizziness and drowsiness
- Headache
- Nausea
Serious adverse effects:
- Respiratory depression and apnea (especially in infants under 6 months — contraindicated)
- Tachycardia and palpitations
- Confusion, disorientation, and delirium (particularly in elderly)
- Acute angle-closure glaucoma (in susceptible individuals)
- Heat stroke (due to suppressed sweating)
- Severe allergic reactions (rare)
Central nervous system effects:
- Nervousness, insomnia
- Confusion, especially in elderly patients
- Hallucinations (rare, higher doses)
Cardiovascular:
- Tachycardia (due to vagal blockade at cardiac M2 receptors)
- Palpitations
Gastrointestinal paradox: While intended to relieve GI spasm, anticholinergic effects can worsen constipation and cause gastroesophageal reflux by reducing lower esophageal sphincter tone.
The elderly are particularly susceptible to anticholinergic adverse effects, including cognitive impairment, urinary retention, and falls. Antimuscarinic burden should be minimized in this population.
Contraindications and warnings
Absolute contraindications:
- Infants less than 6 months of age (risk of respiratory arrest and death)
- Obstructive uropathy or urinary retention
- Obstructive gastrointestinal disease (paralytic ileus, intestinal obstruction, severe ulcerative colitis, toxic megacolon)
- Narrow-angle glaucoma or untreated angle-closure glaucoma
- Myasthenia gravis (may precipitate crisis)
- Hypersensitivity to dicyclomine or anticholinergic drugs
Relative contraindications and warnings:
- Elderly patients: increased risk of confusion, cognitive impairment, and anticholinergic toxicity
- Autonomic neuropathy
- Hepatic or renal impairment (may require dose adjustment)
- Hiatal hernia with reflux esophagitis (may worsen symptoms)
- Coronary artery disease, congestive heart failure, cardiac arrhythmias
- Hyperthyroidism (anticholinergic effects may exacerbate tachycardia)
- Hypertension
- Prostatic hypertrophy (risk of urinary retention)
- Hot weather or fever (impaired heat dissipation due to decreased sweating)
Pregnancy and lactation:
- Pregnancy category B (US): Animal studies show no fetal risk, but human data are limited. Use only if clearly needed.
- Lactation: Dicyclomine is excreted in breast milk and may reduce milk production. It can cause anticholinergic effects in nursing infants including apnea. Breastfeeding is not recommended during treatment.
Pediatric warning: The drug carries a specific warning against use in infants under 6 months due to reports of serious respiratory adverse events including dyspnea, respiratory arrest, asphyxia, and death. This is a high-yield exam point.
Drug interactions
Dicyclomine interacts with numerous medications, primarily through additive anticholinergic effects.
Additive anticholinergic effects (increased toxicity risk):
- Other anticholinergic drugs (antihistamines, tricyclic antidepressants, phenothiazines, antiparkinsonian agents)
- Amantadine
- Antihistamines (diphenhydramine, hydroxyzine)
- Antipsychotics, especially first-generation (chlorpromazine, haloperidol)
- Tricyclic antidepressants (amitriptyline, imipramine)
- MAO inhibitors
- Muscle relaxants (orphenadrine, cyclobenzaprine)
Drugs whose effects may be altered:
- Prokinetic agents (metoclopramide): dicyclomine antagonizes their effects on GI motility
- Potassium chloride tablets: slow dissolution due to delayed gastric emptying may increase local mucosal irritation
- Ketoconazole, itraconazole: reduced absorption due to increased gastric pH and delayed gastric emptying
- Levodopa: delayed gastric emptying may alter absorption
Drugs that may enhance dicyclomine effects:
- Alcohol: additive CNS depression
- CNS depressants (benzodiazepines, opioids, sedative-hypnotics): enhanced sedation and dizziness
Pharmacodynamic interactions:
- Tachycardia-inducing drugs: additive cardiac effects
- Drugs causing urinary retention: compounded risk
Patients should be monitored for enhanced anticholinergic side effects when dicyclomine is combined with any medication having antimuscarinic properties. The cumulative anticholinergic burden is particularly important in elderly patients.
Clinical pearls
High-yield exam and clinical practice points:
- Infant contraindication is critical: Dicyclomine is absolutely contraindicated in infants under 6 months due to case reports of respiratory arrest and death. This was previously used for infantile colic but is no longer recommended. This is a common board exam question.
- Anticholinergic syndrome recognition: Patients presenting with dicyclomine overdose or toxicity exhibit classic anticholinergic toxidrome: "hot as a hare" (hyperthermia), "blind as a bat" (mydriasis), "dry as a bone" (anhidrosis), "red as a beet" (flushing), "mad as a hatter" (delirium). Physostigmine is the antidote for severe central anticholinergic toxicity.
- Elderly prescribing caution: Dicyclomine appears on the Beers Criteria as a potentially inappropriate medication in older adults due to high anticholinergic burden and risk of cognitive impairment, confusion, and falls. Consider alternative therapies for IBS in elderly patients.
- Limited efficacy data: While widely prescribed for IBS, evidence for dicyclomine efficacy is modest. More recent IBS management guidelines favor other approaches including dietary modification, antidepressants (low-dose TCAs or SSRIs), and newer agents.
- Timing of administration: For optimal effect in IBS, dicyclomine should be taken before meals to prevent postprandial cramping, though this is not always specified in prescribing information.
- Driving and machinery warning: Patients should be counseled that dicyclomine may cause drowsiness, dizziness, and blurred vision. Activities requiring alertness should be avoided until individual response is known.
- Heat stroke risk: Warn patients about reduced sweating and impaired heat dissipation, especially in hot climates or during exercise. This can lead to heat exhaustion or heat stroke.
- Glaucoma screening: Before initiating therapy, screen for glaucoma risk factors. Mydriasis from anticholinergics can precipitate acute angle-closure glaucoma in anatomically predisposed individuals.
- Comparison with hyoscyamine: Hyoscyamine is the levorotatory isomer of atropine and has similar antispasmodic effects but may have fewer central side effects compared to dicyclomine in some patients.
Anticholinergic toxidrome: 'Hot as a hare, Blind as a bat, Dry as a bone, Red as a beet, Mad as a hatter' — remember for dicyclomine overdose presentations.
Practice questions
1. A 68-year-old woman with irritable bowel syndrome is started on dicyclomine for abdominal cramping. Three days later, she presents to the emergency department confused and agitated. On examination, her temperature is 38.3°C (101°F), heart rate is 118/min, blood pressure is 145/90 mmHg, and her skin is flushed and dry. Pupils are dilated bilaterally. She has not urinated in 12 hours. Which of the following is the most appropriate immediate treatment?
2. A 32-year-old woman with irritable bowel syndrome is prescribed dicyclomine for abdominal cramping. She asks her physician which medication she should avoid while taking dicyclomine. Which of the following would have the highest risk of additive adverse effects?
3. A mother brings her 4-month-old infant to the pediatrician with excessive crying and apparent abdominal discomfort consistent with colic. The mother read online that dicyclomine might help and asks if it can be prescribed. Which of the following best explains why dicyclomine should not be prescribed for this infant?
Frequently asked questions
How does dicyclomine work for IBS?
Dicyclomine works by blocking muscarinic acetylcholine receptors on smooth muscle in the gastrointestinal tract, reducing parasympathetic stimulation and decreasing intestinal spasm and cramping. This antimuscarinic action provides symptomatic relief of abdominal pain in irritable bowel syndrome. It does not treat the underlying cause of IBS but helps manage acute spasm episodes. The drug also has mild direct smooth muscle relaxant effects independent of receptor blockade.
What are the side effects of dicyclomine?
The most common side effects of dicyclomine are anticholinergic in nature: dry mouth, blurred vision, constipation, urinary hesitancy, dizziness, and drowsiness. Serious adverse effects include tachycardia, confusion and delirium (especially in elderly), acute angle-closure glaucoma in susceptible patients, urinary retention, and heat stroke due to impaired sweating. In infants under 6 months, dicyclomine can cause life-threatening respiratory depression and is contraindicated in this age group.
Is dicyclomine a controlled substance?
No, dicyclomine is not a controlled substance in the United States or most other countries. It does not have abuse potential or risk of dependence. However, it does require a prescription and should be used only under medical supervision due to its anticholinergic effects and potential adverse reactions, particularly in vulnerable populations such as the elderly and those with certain medical conditions like glaucoma or urinary obstruction.
Can dicyclomine cause urinary retention?
Yes, dicyclomine commonly causes urinary hesitancy and can lead to urinary retention, particularly in patients with pre-existing prostatic hypertrophy or bladder outlet obstruction. This occurs because muscarinic receptor blockade reduces bladder detrusor muscle contractility and increases bladder sphincter tone. The drug is contraindicated in patients with obstructive uropathy or established urinary retention. Men with benign prostatic hyperplasia are at especially high risk and should be monitored closely or given alternative therapy.
Dicyclomine vs hyoscyamine — what is the difference?
Both dicyclomine and hyoscyamine are anticholinergic antispasmodics used for IBS and GI spasm, but they differ in structure and receptor selectivity. Hyoscyamine is a natural belladonna alkaloid (the L-isomer of atropine) with potent antimuscarinic effects, while dicyclomine is a synthetic tertiary amine with both antimuscarinic and direct smooth muscle relaxant properties. Hyoscyamine may have slightly faster onset and more predictable pharmacokinetics, while dicyclomine may cause more central nervous system side effects due to better CNS penetration. Both have similar efficacy and anticholinergic side effect profiles.
Conditions it is used for
Related drugs
Sources and further reading
DailyMed (FDA labels)StatPearls (NCBI Bookshelf)MedlinePlusWHO ATC/DDD index: A03AA07
Educational content for medical students, prepared by the WhiteCoat Pro editorial team with AI assistance; every page is reviewed by a second AI model for factual errors. It is not medical advice and does not replace the product label, local guidelines or a clinician.